Trial · NCT02207309
Pazopanib Maintenance Phase II
NCT02207309, Phase 2, Terminated, Ludwig-Maximilians - University of Munich; results first posted 2024-08-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib Maintenance Phase II. Trials, record NCT02207309. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02207309
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib Maintenance Phase II
- NCT number
- NCT02207309
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Ludwig-Maximilians - University of Munich
- Conditions
- Sarcoma
- Interventions
- Pazopanib, Placebo (for Pazopanib)
- First posted
- 2014-08-04
- Last updated
- 2024-08-09
- Other registries' IDs
- eudract:2013-000522-58
- Results first posted
- 2024-08-09
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) | Study Start Dat: June 22, 2015; Study Completion Date: July 29, 2016 ; an approximate study duration of 13 months | The study could not be evaluated. Only one patient was included. |
| Secondary | Overall Survival (OS) | Study Start Dat: June 22, 2015; Study Completion Date: July 29, 2016 ; an approximate study duration of 13 months | The study could not be evaluated. Only one patient was included. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) | Study Start Dat: June 22, 2015; Study Completion Date: July 29, 2016 ; an approximate study duration of 13 months | The study could not be evaluated. Only one patient was included.~Contrary to the original expectation, patients with retroperitoneal or visceral high-risk soft tissue sarcoma were generally not prepared to undergo further therapy with pazopanib for 2 years after multimodal therapy consisting of 8 cycles of chemotherapy in combination with hyperthermia, surgery and, if necessary, radiotherapy, which may have side effects. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Overall Survival (OS) | Study Start Dat: June 22, 2015; Study Completion Date: July 29, 2016 ; an approximate study duration of 13 months |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-free Survival (PFS) | Pazopanib | 1 | Participants | ||
| Progression-free Survival (PFS) | Placebo | 0 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pazopanib | 1 | |
| Overall Study | STARTED | Placebo | 0 | |
| Overall Study | COMPLETED | Pazopanib | 1 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Pazopanib | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pazopanib | 0 | 1 |
| Total, all-cause mortality | Placebo | 0 | 0 |
| Total, other adverse events | Pazopanib | 0 | 1 |
| Total, other adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Pazopanib | 0 | 1 |
| Total, serious adverse events | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02207309
GET https://conductscience.org/api/trials/v1/NCT02207309/registered